CTOs on the Move

GN Resound

www.gnresound.com

 
GN ReSound is the undisputed technology leader in the global hearing instrument market and is one of several divisions of GN Great Nordic. To learn more about our parent company, Great Nordic, please click on the link below.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.gnresound.com
  • 8001 E Bloomington Fwy
    Minneapolis, MN USA 55420
  • Phone: 952.769.8000

Executives

Name Title Contact Details

Similar Companies

Trig Medical

Trig Medical Ltd. is a Ridgefield Park, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lawnwood Regional Medical Center and Heart Institute

Lawnwood Regional Medical Center and Heart Institute is a Fort Pierce, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Eurogentec North America

Eurogentec North America is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ascent Senior Living

Ascent Living Communities is a company that operates senior living communities in Colorado, offering independent living, assisted living, and memory care services.

Berg LLC

BERG is a Boston-based biopharma company focused on taking a bold “back to biology” approach to therapeutic discovery using its unique AI-based Interrogative Biology® platform. This platform combines patient biology and AI-based analytics to engage the differences between healthy and disease environments. The patient’s own biology drives the platform’s results and guides us in the discovery and development of drugs, diagnostics and healthcare applications. Our platform utilizes patient population health data to bring actionable Patient IntelligenceTM to precision medicine applications. For patients this means faster discovery and development of treatments, more effective precision treatments for individuals as well as a reduction in costs to our healthcare systems. BERG has a robust product portfolio in oncology, endocrinology and neurology with mature assets in oncology entering mid and late stage trials. BERG is committed to improving the lives of patients through precision medicine made possible by our innovative platforms.